76 results
8-K
EX-99.1
PRTA
Prothena Corporation plc
8 May 24
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
4:09pm
-amyloid antibody for the treatment of AL amyloidosis designed to directly neutralize soluble toxic light chain aggregates and promote clearance of amyloid
8-K
EX-99.1
PRTA
Prothena Corporation plc
15 Feb 24
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
4:09pm
-in-class amyloid depleter antibody for the treatment of AL amyloidosis designed to directly neutralize soluble toxic light chain aggregates and promote
8-K
EX-99.1
821n2l
8 Jan 24
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
8:35am
8-K
EX-99.1
4gkwr6tk6 7o
2 Nov 23
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
4:09pm
8-K
EX-99.1
z026t5j1hhnvc
3 Aug 23
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
4:10pm
8-K
EX-99.1
uctjo4guant5mf tvgh
4 May 23
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
4:08pm
8-K
EX-1.1
a77skwzf kq
16 Dec 22
Other Events
4:36pm
424B5
xw0rmh vbh4qh67
16 Dec 22
Prospectus supplement for primary offering
4:31pm
424B5
46g82psit
13 Dec 22
Prospectus supplement for primary offering
4:48pm
8-K
EX-99.1
yj4 urqcab49
3 Nov 22
Prothena Reports Third Quarter 2022 Financial Results and Business Highlights
4:24pm
8-K
EX-99.1
vwlwhww7jgcstnx
8 Aug 22
Prothena Reports Second Quarter 2022 Financial Results and Business Highlights
4:27pm